Skye Bioscience (SKYE) Preferred Stock Liabilities (2015 - 2017)
Skye Bioscience (SKYE) posted quarterly Preferred Stock Liabilities of $169447.0 for Q4 2017, down 42.3% year-over-year from $293669.0 in Q4 2016, and down 82.26% quarter-over-quarter from $955045.0 in Q3 2017.
Skye Bioscience (SKYE) Preferred Stock Liabilities (2015 - 2017) Analysis & Trends
Skye Bioscience (SKYE) has reported Preferred Stock Liabilities for 3 consecutive years, with $169447.0 the latest figure, recorded in Q4 2017.
- In Q4 2017, Preferred Stock Liabilities fell 42.3% year-over-year to $169447.0; the TTM figure through Dec 2017 stood at $169447.0 (down 42.3% YoY), while the FY2017 annual figure was $169447.0, down 42.3% from the prior year.
- Preferred Stock Liabilities eased to $169447.0 in Q4 2017 per SKYE's latest filing, from $955045.0 in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $1.4 million in Q4 2015 and bottomed at $169446.0 in Q2 2017.
- Historically, Preferred Stock Liabilities has averaged $847626.6 across 3 years, with a median of $955045.0 in 2017.
- On a YoY basis, Preferred Stock Liabilities climbed as much as 29.77% in 2017 and fell as far as 87.54% in 2017.
- Skye Bioscience's Preferred Stock Liabilities stood at $1.4 million in 2015, then plunged by 78.46% to $293669.0 in 2016, then plunged by 42.3% to $169447.0 in 2017.
- Business Quant data shows SKYE's Preferred Stock Liabilities at $169447.0 in Q4 2017, $955045.0 in Q3 2017, and $169446.0 in Q2 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Skye Bioscience | 10.86 Mn | 10.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 169,447.00 |
| Sep 30, 2017 | 955,045.00 |
| Jun 30, 2017 | 169,446.00 |
| Mar 31, 2017 | 598,135.00 |
| Dec 31, 2016 | 293,669.00 |
| Sep 30, 2016 | 1.36 Mn |
| Jun 30, 2016 | 1.36 Mn |
| Mar 31, 2016 | 1.36 Mn |
| Dec 31, 2015 | 1.36 Mn |